More Than 450 Companies Adopt Veeva RIM for Regulatory Information Management, Driving Efficiency and Compliance with New Industry Partnerships
PorAinvest
martes, 2 de septiembre de 2025, 7:05 am ET1 min de lectura
VEEV--
The adoption of Veeva RIM is part of Veeva's broader strategy to enhance collaboration with global health authorities and drive efficiency and compliance. The company has formed strategic partnerships with Accumulus Technologies and DNAnexus to integrate multi-health authority platforms, further streamlining regulatory processes.
Veeva RIM is designed to streamline global regulatory processes on a single, cloud-based platform. It is part of Veeva Development Cloud, the technology foundation for product development across clinical, quality, regulatory, and safety. The platform offers continuous publishing capabilities, with more than 85 organizations using it to reduce rework and accelerate submission timelines.
The partnership with Accumulus Technologies aims to connect the Accumulus platform with Veeva RIM for greater interoperability, facilitating seamless regulatory submissions to a network of over 70 regulatory agencies worldwide. Similarly, the integration with DNAnexus Trusted Regulatory Spaces (TRS) is expected to provide best-in-class data sharing capabilities for inter-agency collaboration and faster regulated product approvals.
The adoption of Veeva RIM by such a large number of biopharmaceutical companies indicates a strong market demand for advanced regulatory solutions. As regulatory environments become increasingly complex, companies are looking for technologies that can help them navigate these challenges more efficiently.
Veeva Systems' continued innovation in regulatory information management and its strategic partnerships position it well to meet the evolving needs of the life sciences industry.
References:
[1] https://www.prnewswire.com/news-releases/more-than-450-companies-drive-speed-to-market-with-veeva-rim-302542568.html
[2] https://www.stocktitan.net/news/ZBIO/zenas-bio-pharma-and-royalty-pharma-enter-into-obexelimab-funding-7z5dhoqcc9sm.html
Veeva Systems announced over 450 companies, including 19 of the top 20 biopharmas, have adopted Veeva RIM for regulatory information management on a unified platform. The company's advanced regulatory capabilities and new industry partnerships with Accumulus Technologies and DNAnexus aim to accelerate collaboration with global health authorities and drive efficiency and compliance. Veeva RIM streamlines global regulatory processes on a single, cloud-based platform and is part of Veeva Development Cloud.
Veeva Systems (NYSE: VEEV) has announced a significant milestone in its regulatory information management (RIM) capabilities, with over 450 companies, including 19 of the top 20 biopharmaceutical companies, adopting Veeva RIM on a unified platform. This adoption underscores the growing demand for advanced regulatory solutions in the life sciences industry.The adoption of Veeva RIM is part of Veeva's broader strategy to enhance collaboration with global health authorities and drive efficiency and compliance. The company has formed strategic partnerships with Accumulus Technologies and DNAnexus to integrate multi-health authority platforms, further streamlining regulatory processes.
Veeva RIM is designed to streamline global regulatory processes on a single, cloud-based platform. It is part of Veeva Development Cloud, the technology foundation for product development across clinical, quality, regulatory, and safety. The platform offers continuous publishing capabilities, with more than 85 organizations using it to reduce rework and accelerate submission timelines.
The partnership with Accumulus Technologies aims to connect the Accumulus platform with Veeva RIM for greater interoperability, facilitating seamless regulatory submissions to a network of over 70 regulatory agencies worldwide. Similarly, the integration with DNAnexus Trusted Regulatory Spaces (TRS) is expected to provide best-in-class data sharing capabilities for inter-agency collaboration and faster regulated product approvals.
The adoption of Veeva RIM by such a large number of biopharmaceutical companies indicates a strong market demand for advanced regulatory solutions. As regulatory environments become increasingly complex, companies are looking for technologies that can help them navigate these challenges more efficiently.
Veeva Systems' continued innovation in regulatory information management and its strategic partnerships position it well to meet the evolving needs of the life sciences industry.
References:
[1] https://www.prnewswire.com/news-releases/more-than-450-companies-drive-speed-to-market-with-veeva-rim-302542568.html
[2] https://www.stocktitan.net/news/ZBIO/zenas-bio-pharma-and-royalty-pharma-enter-into-obexelimab-funding-7z5dhoqcc9sm.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios